Twelve abstracts and two late-breaking presentations demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing research across a spectrum of dermatologic conditions and aesthetic indications
Enables millions of Indians to monitor their vitals without the need of any additional device
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Data published in the prestigious journal ACS Central Science of the American Chemical Society
Inconsistent antibody performance is a significant challenge for researchers and sits at the heart of the reproducibility crisis observed in biomedical research
The Karnataka Health Promotion Trust held a day-long session in New Delhi to address health care challenges
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
Amit Jaju, Senior Managing Director, India in an interview with Thomas C Thottathil outlined the steps Indian pharma companies should follow to be compliant with global regulatory requirements
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Subscribe To Our Newsletter & Stay Updated
